Literature DB >> 7531409

Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin.

W N Hait1, J F Gesmonde, J S Lazo.   

Abstract

Antipsychotic drugs that bind to and inhibit the action of calmodulin also inhibit cellular proliferation. In addition these drugs are cytotoxic to most malignant cells and can augment the antiproliferative and cytotoxic effects of bleomycin. They are attractive candidates for use against tumors of the central nervous system since they readily pass the blood-brain barrier and accumulate in the brain. To identify more active derivatives, we studied the effect of a series of phenothiazines and a group of related compounds alone or in combination with bleomycin against rat glioblastoma cell lines. C6 cells were grown for 24 hours prior to a 48 hour exposure to anti-psychotic drug alone or to an IC20 concentration of antipsychotic drug with bleomycin. Cells were stained with methylene blue and enumerated spectrophotometrically. Eight phenothiazines were found to augment the effect of bleomycin by > or = 3-fold. These included 1-chlorpromazine (3.8x), chlorpromazine (3.2x), 3-chlorpromazine (3.0x), 4-chlorpromazine (3.4x), thiomethylpromazine (3.3x), didesmethylchlorpromazine (11x), fluphenazine (5.5x) and trifluoperazine (3.2x). Structurally similar compounds also having activity included trans-flupenthixol (6.0x), 2-chloroimipramine (6.0x), desipramine (22x), and penfluridol (24x). There was a direct correlation between the antiproliferative effect of anticalmodulin compounds and the ability of these drugs to inhibit the activation of calmodulin-sensitive phosphodiesterase. However, there was no correlation between the inhibition of calmodulin and the augmentation of the antiproliferative activity of bleomycin. Penfluridol, one of the most active compounds, was chosen for further study. It increased the activity of bleomycin against L1210 leukemic cells by 90-fold and MCF-7 human breast cancer cells by 4-fold. The effect of penfluridol in combination with bleomycin was due to increased cytotoxicity as measured by clonogenic assay.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531409

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants.

Authors:  K L Jensen-Pergakes; M A Kennedy; N D Lees; R Barbuch; C Koegel; M Bard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Authors:  D Sanglard; F Ischer; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site.

Authors:  N Jia; B Arthington-Skaggs; W Lee; C A Pierson; N D Lees; J Eckstein; R Barbuch; M Bard
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

4.  Disruption of the Candida albicans CYB5 gene results in increased azole sensitivity.

Authors:  K M Rogers; C A Pierson; N T Culbertson; C Mo; A M Sturm; J Eckstein; R Barbuch; N D Lees; M Bard
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy.

Authors:  M Cemazar; C S Parkins; A L Holder; D J Chaplin; G M Tozer; G Sersa
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

Review 6.  Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent.

Authors:  Nguyen Minh Tuan; Chang Hoon Lee
Journal:  Molecules       Date:  2019-10-11       Impact factor: 4.411

Review 7.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.